Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
7 Articles
7 Articles
Sanofi will pay at least $1 billion to Regeneron to develop four new antibodies. A strategic agreement to prepare the post-Dupixent, the leading drug of the French group, whose exclusivity will end in the early 2030s.
Health: Sanofi Signs a $1 Billion Deal with Regeneron to Produce the Successors of the Dupixent Drug
The French pharmaceutical group Sanofi again joins with the American laboratory Regeneron to develop the successors of its star medicine Sanofi will pay at least one billion
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
Oct 1 (Reuters) - French drugmaker Sanofi said on Thursday it would pay US partner Regeneron $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology antibodies to the partnership ...
(Teleborsa) - Regeneron Pharmaceuticals and Sanofi have announced the expansion of their historic cooperation in the field of antibodies, including in the alliance several new generation antibodies for a long time...
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
